A RANDOMIZED CONTROLLED TRIAL OF RIFAXIMIN IN INDIVIDUALS WITH HIV ON LONG-TERM ART
Ongoing immune activation plays a key role in clinical outcomes of people living with HIV during long-term combination antiretroviral therapy (cART); the forces responsible for elevated immune activation (IA) remain uncertain. Microbial translocation from the gastrointestinal tract have been reported to contribute to immune activation, and a modest reduction of IA with use of the…